ERBB2 and cancer: The observation that the engineered B14.3 HER2 cells were resistant to Trastuzumab-mediated growth inhibition in vitro meant that any therapeutic benefits of the conjugates observed in vivo in the cancer model must be exclusively driven by the immune system.